NCT02226549 - Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

LDV/SOF

LDV/SOF (90/400 mg) FDC tablet administered orally once daily

DRUG

VDV

VDV 80 mg tablet administered orally once daily

DRUG

RBV

RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (1)

Unknown

San Antonio